本帖最后由 老马 于 2012-1-13 21:20 编辑 6 E; b8 x- o2 \" W7 \8 j# D: p
8 g4 E$ l/ [9 T- H/ h爱必妥和阿瓦斯丁的比较
- Q! ~7 T/ s1 ^
/ H$ |' M; Y. \& c: l0 S9 xhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
8 z" F/ {- i' q" v. |& |3 W! J
5 Q- F8 g" U8 A, S
$ ^0 D5 F" V& f: B% U
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( n( p7 D7 d8 K: S: z
==================================================( M1 W2 x! s a4 G: x
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)6 k+ N0 d( D7 H. t) w7 r
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
- j/ ^3 W4 p' R; ]0 Y( R- mResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 @4 K5 X+ b5 g0 ~1 Q$ [
|